Home Page - Slider

Reproductive Testing
Genetic Counseling
informaSeq Prenatal Test
VistaSeq Hereditary Cancer Testing
reproductive testing
Reproductive Testing

Integrated Genetics is a leading provider of reproductive genetic testing services

 

LabCorp Successfully Completes Acquisition of Sequenom, Inc.

“With the addition of Sequenom, LabCorp is a market leader for non-invasive prenatal testing, women’s health and reproductive genetics,” said David P. King, Chairman and Chief Executive Officer of LabCorp. 

 

 

genetic counseling
Genetic Counseling

Grounded in Experience. Driving Innovation.

 

Vistaseq
VistaSeqSM Hereditary Cancer Panel

Because Knowledge is a Powerful Tool

 

 

For Patients

To learn about your genetic testing options, please visit www.mytestingoptions.com  

Working with Integrated Genetics

Integrated Genetics Highlights

“With the addition of Sequenom, LabCorp is a market leader for non-invasive prenatal testing, women’s health and reproductive genetics,” said David P. King, chairman and chief executive officer of LabCorp. “This strategic acquisition also expands our reach both domestically and internationally and furthers our mission to improve health and improve lives around the globe.”

On July 28th the American College of Medical Genetics and Genomics (ACMG) released an updated statement that highlights the information health care providers should discuss with patients when considering prenatal aneuploidy screening options.  To read position statement, please visit http://www.nature.com/gim/journal/vaop/ncurrent/pdf/gim201697a.pdf

Now the Largest Open BRCA Datashare of Curated BRCA Variants Clinically Suitable for Patient Management 

​A comprehensive suite of testing options to identify BRCA 1 and 2 mutations associated with breast, ovarian and certain other cancers.

Analysis of over 7,400 mutations found in 142 different genes, associated with more than 114 different inherited diseases

An assessment of genetic mutations within a panel of 27 genes known to be associated with hereditary cancer syndromes. 

An advanced, non-invasive prenatal screening for T21, T18, and T13 chromosomal aneuploidies using next generation technology that can be administered as early as 10 weeks gestation.